Literature DB >> 12065472

Assessment of virulence of uropathogenic Escherichia coli type 1 fimbrial mutants in which the invertible element is phase-locked on or off.

Nereus W Gunther1, Jennifer A Snyder, Virginia Lockatell, Ian Blomfield, David E Johnson, Harry L T Mobley.   

Abstract

Type 1 fimbria is a proven virulence factor of uropathogenic Escherichia coli (UPEC), causing urinary tract infections. Expression of the fimbria is regulated at the transcriptional level by a promoter situated on an invertible element, which can exist in one of two different orientations. The orientation of the invertible element that allows the expression of type 1 fimbriae is defined as "on," and the opposite orientation, in which no transcription occurs, is defined as "off." During the course of a urinary tract infection, we have observed that the infecting E. coli population alternates between fimbriated and nonfimbriated states, with the fimbriated on orientation peaking at 24 h. We propose that the ability of the invertible element to switch orientations during infection is itself a virulence trait. To test this hypothesis, nucleotide sequence changes were introduced in the left inverted repeat of the invertible element of UPEC pyelonephritis strain CFT073 that locked the invertible elements permanently in either the on or the off orientation. The virulence of these mutants was assessed in the CBA mouse model of ascending urinary tract infection at 4, 24, 48, and 72 h postinoculation (hpi). We conducted independent challenges, in which bladders of mice were inoculated with either a single mutant or the wild type, and cochallenges, in which a mutant and the wild type were inoculated together to allow direct competition in the urinary tract. In both sets of experimental infections, the locked-off mutant was recovered from the urine, bladder, and kidneys in significantly lower numbers than the wild type at 24 hpi (P < or = 0.05), demonstrating its attenuation. Conversely, the locked-on mutant was recovered in higher numbers than the wild type at 24 hpi (P < or = 0.05), showing enhanced virulence of this mutant. No significant differences were seen between the mutants and wild type in the urine or the bladder at 48 or 72 hpi. However, the wild type outcompeted the locked-off mutant in the kidneys during the cochallenge experiment at 72 hpi (P = 0.009). Overall, these data suggest that the ability of the invertible element controlling type 1 fimbria expression to phase vary contributes significantly to virulence early (24 hpi) in the course of a urinary tract infection by UPEC and most profoundly influences colonization of the bladder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065472      PMCID: PMC128061          DOI: 10.1128/IAI.70.7.3344-3354.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  33 in total

Review 1.  Toll-like receptor signaling and chemokine receptor expression influence the severity of urinary tract infection.

Authors:  C Svanborg; B Frendéus; G Godaly; L Hang; M Hedlund; C Wachtler
Journal:  J Infect Dis       Date:  2001-03-01       Impact factor: 5.226

2.  Regulatory cross-talk between adhesin operons in Escherichia coli: inhibition of type 1 fimbriae expression by the PapB protein.

Authors:  Y Xia; D Gally; K Forsman-Semb; B E Uhlin
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

3.  Type 1 fimbriae deliver an LPS- and TLR4-dependent activation signal to CD14-negative cells.

Authors:  M Hedlund; B Frendéus; C Wachtler; L Hang; H Fischer; C Svanborg
Journal:  Mol Microbiol       Date:  2001-02       Impact factor: 3.501

4.  Immunofluorescence study of fimbrial phase variation in Escherichia coli KS71.

Authors:  B Nowicki; M Rhen; V Väisänen-Rhen; A Pere; T K Korhonen
Journal:  J Bacteriol       Date:  1984-11       Impact factor: 3.490

5.  Phase variation of type 1 fimbriae in Escherichia coli is under transcriptional control.

Authors:  B I Eisenstein
Journal:  Science       Date:  1981-10-16       Impact factor: 47.728

6.  In vivo detection of Escherichia coli type 1 fimbrial expression and phase variation during experimental urinary tract infection.

Authors:  C Struve; K A Krogfelt
Journal:  Microbiology       Date:  1999-10       Impact factor: 2.777

7.  In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during experimental urinary tract infection.

Authors:  N W Gunther; V Lockatell; D E Johnson; H L Mobley
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Contribution of adhesion to bacterial persistence in the mouse urinary tract.

Authors:  L Hagberg; R Hull; S Hull; S Falkow; R Freter; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

9.  Role of type 1 fimbriae in the pathogenesis of ascending urinary tract infection induced by escherichia coli in mice.

Authors:  T Iwahi; Y Abe; M Nakao; A Imada; K Tsuchiya
Journal:  Infect Immun       Date:  1983-03       Impact factor: 3.441

10.  Ascending, unobstructed urinary tract infection in mice caused by pyelonephritogenic Escherichia coli of human origin.

Authors:  L Hagberg; I Engberg; R Freter; J Lam; S Olling; C Svanborg Edén
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

View more
  56 in total

1.  Decreased expression of type 1 fimbriae by a pst mutant of uropathogenic Escherichia coli reduces urinary tract infection.

Authors:  Sébastien Crépin; Sébastien Houle; Marie-Ève Charbonneau; Michaël Mourez; Josée Harel; Charles M Dozois
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

Review 2.  Phase and antigenic variation in bacteria.

Authors:  Marjan W van der Woude; Andreas J Bäumler
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

Review 3.  Fimbrial phase variation: stochastic or cooperative?

Authors:  Surabhi Khandige; Jakob Møller-Jensen
Journal:  Curr Genet       Date:  2015-11-04       Impact factor: 3.886

4.  Characterization of urinary tract infection-associated Shiga toxin-producing Escherichia coli.

Authors:  Francisco Toval; Roswitha Schiller; Iris Meisen; Johannes Putze; Ivan U Kouzel; Wenlan Zhang; Helge Karch; Martina Bielaszewska; Michael Mormann; Johannes Müthing; Ulrich Dobrindt
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

5.  Evaluation of CpxRA as a Therapeutic Target for Uropathogenic Escherichia coli Infections.

Authors:  Lana Dbeibo; Julia J van Rensburg; Sara N Smith; Kate R Fortney; Dharanesh Gangaiah; Hongyu Gao; Juan Marzoa; Yunlong Liu; Harry L T Mobley; Stanley M Spinola
Journal:  Infect Immun       Date:  2018-02-20       Impact factor: 3.441

6.  Macrophages rapidly transfer pathogens from lipid raft vacuoles to autophagosomes.

Authors:  Amal O Amer; Brenda G Byrne; Michele S Swanson
Journal:  Autophagy       Date:  2005-04-04       Impact factor: 16.016

7.  Effects of ibeA deletion on virulence and biofilm formation of avian pathogenic Escherichia coli.

Authors:  Shaohui Wang; Chunling Niu; Zhenyu Shi; Yongjie Xia; Muhammad Yaqoob; Jianjun Dai; Chengping Lu
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

8.  complex interplay between type 1 fimbrial expression and flagellum-mediated motility of uropathogenic Escherichia coli.

Authors:  M Chelsea Lane; Amy N Simms; Harry L T Mobley
Journal:  J Bacteriol       Date:  2007-05-18       Impact factor: 3.490

9.  In vivo gene expression analysis identifies genes required for enhanced colonization of the mouse urinary tract by uropathogenic Escherichia coli strain CFT073 dsdA.

Authors:  Brian J Haugen; Shahaireen Pellett; Peter Redford; Holly L Hamilton; Paula L Roesch; Rodney A Welch
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

10.  A conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility.

Authors:  Michael D Engstrom; Christopher J Alteri; Harry L T Mobley
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.